- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued based on future growth
Swiss Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Cosmo Pharmaceuticals
Market Cap: CHF 932.4m
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 58.50
7D
-8.0%
1Y
-21.6%
Newron Pharmaceuticals
Market Cap: CHF 137.5m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 6.89
7D
-1.9%
1Y
-18.8%